PROTEINURIA IN NEPHROTIC RANGE

Clinical trials for PROTEINURIA IN NEPHROTIC RANGE explained in plain language.

Never miss a new study

Get alerted when new PROTEINURIA IN NEPHROTIC RANGE trials appear

Sign up with your email to follow new studies for PROTEINURIA IN NEPHROTIC RANGE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet recruiting 1

New hope for cancer patients facing kidney damage from treatment

Disease control Not yet recruiting

This study is testing a drug called sparsentan to see if it can reduce severe proteinuria, a type of kidney damage, in cancer patients. The damage is caused by a specific class of anti-cancer drugs. The goal is to control this side effect so patients can continue their cancer tre…

Matched conditions: PROTEINURIA IN NEPHROTIC RANGE

Phase: PHASE1 • Sponsor: Brigham and Women's Hospital • Aim: Disease control

Last updated Mar 09, 2026 14:25 UTC

PROTEINURIA IN NEPHROTIC RANGE

Get alerted when new PROTEINURIA IN NEPHROTIC RANGE trials appear

New hope for cancer patients facing kidney damage from treatment